A New Hope for Pancreatic Cancer: PARP Inhibition in Tumors With BRCA Mutations
  • CME

Learn about PARP inhibition in BRCA-positive pancreatic cancer from 3 renowned experts.
John L. Marshall, MD
Program Director
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Eileen M. O'Reilly, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 8, 2019 Expiration: March 7, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in pancreatic ductal adenocarcinoma with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitors as monotherapy or in combination with other agents in pancreatic ductal adenocarcinoma

Information on this Educational Activity

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received funds for research support, consulting fees, and fees for non-CME activities from Amgen, Bayer, Caris, Celgene, Merck, Roche/Genentech, and Taiho.


Tanios Bekaii-Saab, MD, FACP

Mayo Clinic College of Medicine and Science
Leader, GI Cancer Program
Mayo Clinic Center
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from AbbVie, Armo Biosciences, Imugene, Immuneering, and Sillajen.
Eileen M. O'Reilly, MD

Winthrop Rockefeller Chair in Medical Oncology
Section Head, 
Hepatopancreaticobiliary/Neuroendocriine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York

Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support ActaBiologica, Agios, Array, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, MabVax, Novartis, OncoQuest, Polaris, Puma, QED, and Roche and consulting fees from 3DMedcare, Agios, AlignMed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, BeiGene, Bioline, Bristol-Myers Squibb, Boston Scientific, Bridgebio, CARsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Gilead Sciences, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Janssen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, NewLink Genetics, Novella, Onxeo, PCI Biotech, Pfizer, PharmaCyte, Pharmacyclics, Pieris, QED, RedHill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vivus, Yakult, and Yiviva.


Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME activities from Genomic Health, Lilly, and Merck.
Brandon May

Editorial Contributor

Brandon May has no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with pancreatic cancer.


The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with pancreatic cancer.

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 08, 2019, through March 07, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas.

person default Stephen J. Schuster, MD Released: December 6, 2019

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL.

Jae H. Park, MD Released: December 6, 2019

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

James K. Kochenderfer, MD Released: December 6, 2019

In this slideset from Clinical Care Options, experts provide insights into the optimal management of toxicities associated with CAR T-cell therapy.

Matthew J. Frigault, MD Released: December 6, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?